Home · Peptide Library · Mounjaro
Mounjaro
Mounjaro is the FDA-approved type 2 diabetes drug from Eli Lilly. It's a once-weekly injection of tirzepatide, the same active ingredient in Zepbound, approved specifically for blood sugar control in diabetes.
- Active ingredient
- Tirzepatide
- Prescribed dose
- 2.5–15 mg weekly (titrated)
- Manufacturer
- Eli Lilly
- FDA approved
- 2022 · Type 2 diabetes
Dosing requires prescription and clinical supervision. Talk to your healthcare provider about whether Mounjaro is right for you.
Quick Answer
Mounjaro is FDA-approved for type 2 diabetes. People on it typically drop their A1c by about 2.3 points at the higher doses. If your A1c is 8.5, that's a drop to around 6.2. It's the same drug as Zepbound, just labeled for diabetes instead of weight loss. The dose ladder is identical (tirzepatide 2.5mg up to 15mg weekly). In a 2021 head-to-head trial against Ozempic, Mounjaro came out on top on both A1c reduction and weight loss. Below: what the trials actually show, how it compares to Ozempic, and the side effects worth knowing.
What is Mounjaro?
Mounjaro is the brand-name version of tirzepatide made by Eli Lilly for type 2 diabetes. The FDA approved it in 2022. It's prescribed for adults with type 2 diabetes whose blood sugar isn't controlled by diet, exercise, and metformin alone. Mounjaro is the same active ingredient as Zepbound, just labeled for a different reason. Mounjaro treats diabetes. Zepbound treats obesity. The molecule and dose ladder are identical.
How it works
Mounjaro mimics two of your body's natural hormones at once. Scientists call them GLP-1 and GIP. Both get released by your gut when you eat. GLP-1 tells your pancreas to release insulin when blood sugar rises. It also tells your brain you're full and slows down digestion. GIP improves how your body handles sugar and adds extra appetite suppression. Mounjaro is a long-lasting copy of both. It activates both receptors more strongly than your body's own hormones. And it stays in your system for about a week per dose. The two-receptor mechanism is what makes Mounjaro stronger than Ozempic on A1c reduction. Ozempic hits one receptor. Mounjaro hits two.
How Mounjaro compares
Mounjaro vs Zepbound
Same drug, different brand. Here's what that actually means for you.
Mounjaro and Zepbound are the same drug. That drug is tirzepatide, made by Eli Lilly. The molecule and dose ladder are identical. The difference is what each is FDA-approved for. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. What this means for you. If you have type 2 diabetes and you're trying to manage blood sugar, Mounjaro is the standard. If you don't have diabetes and your goal is weight loss, Zepbound is the FDA-approved choice. The drug works the same way at the same doses. The label, the insurance code, and the manufacturer assistance program differ.
Mounjaro vs Ozempic
The two FDA-approved type 2 diabetes brands. Here's where each wins.
Mounjaro and Ozempic are both FDA-approved for type 2 diabetes. Mounjaro produces more A1c reduction. In a 2021 head-to-head trial, people on Mounjaro dropped their A1c by about 2.3 points at 40 weeks. People on Ozempic dropped about 1.9 points. Mounjaro also produced more weight loss as a side benefit, about 25 pounds versus 14 pounds at 200-pound baseline. Why the gap? Mounjaro mimics two of your body's natural hormones at once: GLP-1 plus GIP. Ozempic mimics one: GLP-1. The second hormone improves how your body handles sugar through a separate pathway and adds extra appetite suppression. What Ozempic still wins on. The deepest cardiovascular evidence in the diabetes population. SUSTAIN-6 enrolled 3,297 adults with type 2 diabetes and high heart risk. Ozempic cut their major heart events by 26% over about two years. Mounjaro's cardiovascular outcomes trial is still running. Until that data lands, Ozempic is the option with proven heart protection in the diabetes population. What this means for you. If you need maximum A1c reduction, Mounjaro is the stronger choice. If you have diabetes and existing heart disease, Ozempic is the option with proven cardiovascular benefit today.
Approval status
Mounjaro got FDA approval in 2022 for type 2 diabetes. The SURPASS trial program established efficacy across multiple groups. SURPASS-1 covered drug-naive patients. SURPASS-2 was the head-to-head against Ozempic. Mounjaro came out on top, dropping A1c about 2.3 points versus 1.9 points over 40 weeks. SURPASS-3 through 5 covered patients on background diabetes therapies including insulin. The cardiovascular outcomes trial (SURPASS-CVOT) is still running. Topline data is expected in 2026.
Who should not take Mounjaro
This page is informational only. Whether Mounjaro is appropriate for you depends on your full medical history, current medications, and personal risk factors. Discuss with your healthcare provider for a personalized assessment.
Emerging safety evidence
Bone mineral density emerged as a consideration in a 2026 head-to-head retrospective (Liu et al., J Clin Endocrinol Metab). The study followed 255 GLP-1 RA users against 255 matched controls over 17 months. In people with diabetes, which is Mounjaro's main population, bone density loss was similar between the GLP-1 group and matched controls. The diabetes-specific bone story stayed quiet. In people without diabetes (off-label Mounjaro territory), the GLP-1 group lost modestly more bone at the total hip, -1.0% versus -0.6% in controls. Within the GLP-1 group, bone loss correlated with weight loss. That suggests the effect is weight-loss-mediated rather than a direct drug action. The pattern matches what's seen with bariatric surgery and severe caloric restriction. Fracture-outcome data is still maturing. We don't know yet whether the bone-density signal becomes a fracture problem. Particularly relevant if you're at baseline fracture risk: post-menopausal, older adult, prior osteopenia, or prior osteoporosis.
Common questions
Is Mounjaro the same as Zepbound?
Same drug, different brand. Both are tirzepatide made by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The molecule and the dose ladder are identical. The labels and insurance codes differ.
How much does Mounjaro lower A1c?
About 2.3 points on average at the higher doses in the FDA-approval trials. If your A1c is 8.5, that's a drop to around 6.2. About 80% of people on the 15mg dose got below 7%. About half got below 6.5%. Lower doses (5mg, 10mg) drop A1c by about 1.9 to 2.1 points. Real-world results vary based on your starting A1c, your diet, your other diabetes medications, and how consistently you take it.
How much weight do you lose on Mounjaro?
About 15 to 25 pounds in the FDA-approval trials over 40 weeks, depending on the dose. Less than Zepbound at the same dose because the diabetes population starts at a different baseline weight. The 15mg dose, the highest, gets closest to 25 pounds. Most weight loss happens in the first 6 to 9 months. Discontinuation reverses about two-thirds of the loss within a year if you stop the drug.
What are the side effects of Mounjaro?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation. They tend to be worst at dose escalation and ease over a few weeks. Less common but serious: gallbladder disease, pancreatitis. Hypoglycemia is rare with Mounjaro alone but can happen if you're also on insulin or sulfonylureas. A 2026 retrospective also showed modest extra bone-density loss in adults without diabetes who lost weight on a GLP-1. Fracture-outcome data isn't there yet.
Does Mounjaro reduce heart attack risk?
Probably yes, but the trial data isn't complete yet. The SURPASS-CVOT trial is testing whether Mounjaro cuts major heart events in adults with type 2 diabetes and high heart risk. Topline data is expected in 2026. Until that lands, Ozempic is the only GLP-1 with FDA-approved cardiovascular protection in diabetes. Wegovy is the only one with FDA-approved cardiovascular protection in obesity without diabetes. Mounjaro's heart story is still being written.
What other GLP-1 options exist besides Mounjaro?
Ozempic (semaglutide) is a single-receptor GLP-1. Mounjaro beat Ozempic head-to-head on A1c in SURPASS-2. Zepbound is the same molecule as Mounjaro, approved for weight loss instead of diabetes. Victoza (liraglutide) is a daily injection with a smaller glucose-lowering effect. Retatrutide is an investigational triple-receptor GLP-1 in Phase 3 trials.
Full research profile
The full tirzepatide research profile covers the complete SURPASS and SURMOUNT trial programs, dual GIP/GLP-1 mechanism, head-to-head comparison with semaglutide, sleep apnea outcomes, and the emerging retatrutide triple agonist context.
Mounjaro and Zepbound share the same active ingredient: tirzepatide. The full PSI tirzepatide page covers the SURPASS diabetes trial data side by side with the SURMOUNT weight-loss data. It also covers the head-to-head outcomes against semaglutide, the bone density signal, and how the evidence compares against the next-generation triple agonist retatrutide.
View full Tirzepatide research profile →Comparisons
Related brands
Related research
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.